ロード中...
Increased sodium channel use-dependent inhibition by a new potent analogue of tocainide greatly enhances in vivo antimyotonic activity
Although the sodium channel blocker, mexiletine, is the first choice drug in myotonia, some myotonic patients remain unsatisfied due to contraindications, lack of tolerability, or incomplete response. More therapeutic options are thus needed for myotonic patients, which require clinical trials based...
保存先:
| 出版年: | Neuropharmacology |
|---|---|
| 主要な著者: | , , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Pergamon Press
2017
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5154332/ https://ncbi.nlm.nih.gov/pubmed/27743929 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.neuropharm.2016.10.013 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|